Related Experiment Videos
Changing from oral to depot fluphenazine
1Department of Psychiatry, Medical College of Pennsylvania at Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129.
The Journal of Clinical Psychiatry
|September 1, 1988
Summary
High doses of depot fluphenazine can cause problems during medication changes. A new method using updated pharmacokinetic data and clinical experience offers a better approach for dose conversion in schizophrenia treatment.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Pharmacy
Background:
- Switching patients from oral to depot fluphenazine formulations can lead to adverse events.
- Current dose conversion formulas often result in excessively high dosages of depot fluphenazine.
- These high doses may contribute to treatment complications and reduced patient adherence.
Purpose of the Study:
- To propose a novel method for converting oral fluphenazine to depot fluphenazine.
- To address the issue of high-dose related problems in depot fluphenazine therapy.
- To optimize dose conversion strategies based on current scientific understanding and clinical practice.
Main Methods:
- Review of recent pharmacokinetic data for fluphenazine decanoate.
- Analysis of low-dose treatment strategies in schizophrenia management.
- Integration of the authors' clinical experience in dose conversion.
Main Results:
- The proposed method aims to achieve more accurate and safer dose conversions.
- It is expected to minimize the occurrence of adverse events associated with high initial depot doses.
- This approach facilitates smoother transitions between oral and depot formulations.
Conclusions:
- A revised approach to fluphenazine decanoate dose conversion is necessary.
- Utilizing updated pharmacokinetic information and clinical insights can improve patient outcomes.
- This strategy supports more effective and safer long-term treatment for schizophrenia.